Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-clinical novel T cell engager (TCE) with first-in-class potential BMX-502 is a bispecific antibody ...
Tobias Kammann from the Center for Infectious Medicine (CIM) at the Department of Medicine, Huddinge (MedH) is defending his thesis titled "The diversity of MAIT cells across the human body and in ...
Dr. Simon Plyte, Biomunex’s CSO, has been invited to present MAIT engagers preclinical data during an oral communication at 2025 SITC Annual meeting With a very attractive safety and efficacy profile, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback